Abbas Hussain - GlaxoSmithKline PLC President Global Pharmaceuticals

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

  President
Mr. Abbas Hussain is President Global Pharmaceuticals of the Company. He joined CET in 2008 and was appointed President, Global Pharmaceuticals in 2014, having joined the company as President, Emerging Markets Asia Pacific in 2008. He joined the ViiV Healthcare Ltd Board in October 2009. Previously, he spent 20 years at Eli Lilly where he held positions including President, Europe. He also worked for Eli Lilly in Australia, the US, India, Turkey and Germany in several roles, including business development, sales and marketing, and management. He has a degree in Medicinal Chemistry Pharmacology from Loughborough University and was born in Madras, India. In January 2017, GSK announced Abbas decision to leave the company later in the year.
  President Since 2014      
(44) 20 8047 7807  www.gsk.com

GlaxoSmithKline PLC Management Efficiency

GlaxoSmithKline PLC has Return on Asset of 7.78 % which means that on every $100 spent on asset it made $7.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 50.81 %, implying that it generated $50.81 on every 100 dollars invested. GlaxoSmithKline PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to increase to 23.20. The current Return on Average Assets is estimated to increase to 0.07GlaxoSmithKline PLC Return on Average Assets are decreasing as compared to previous years. The last year's value of Return on Average Assets was reported at 0.07. The current Tangible Assets Book Value per Share is estimated to increase to 14.38, while Goodwill and Intangible Assets are estimated to decrease to under 32.9 B. The current Total Liabilities is estimated to decrease to about 57 B. The current Current Liabilities is estimated to decrease to about 22.5 B
The company has 36.63 B in debt with debt to equity (D/E) ratio of 1.59, which is OK given its current industry classification. GlaxoSmithKline PLC has a current ratio of 0.85, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Samuel MoedBristol Myers Squibb
2012
Maria CroweEli Lilly And
2012
Ruud DobberAstrazeneca PLC
2019
Paul BiondiBristol Myers Squibb
2018
Louis SchmuklerBristol Myers Squibb
2019
Katie WatsonGilead Sciences
N/A
Fionnuala WalshEli Lilly And
2007
Melissa BarnesEli Lilly And
2013
James MeyersGilead Sciences
2016
Kathryn MetcalfeBristol Myers Squibb
2020
Ann JudgeBristol Myers Squibb
2016
Ramon RocaGrifols S A
2014
Ann PowellBristol Myers Squibb
2016
Joshua SmileyEli Lilly And
2018
Johna NortonEli Lilly And
2017
David ElkinsBristol Myers Squibb
2019
Sean BohenAstrazeneca PLC
2015
Adam DubowBristol Myers Squibb
2018
Stephen FryEli Lilly And
2011
Aarti ShahEli Lilly And
2018
Taiyin YangGilead Sciences
2015

Company Summary

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.GlaxoSmithKline PLC (GSK) is traded on BATS Exchange in USA. It is located in 980 Great West Road, Brentford, Middlesex TW8 9GS, United Kingdom and employs 99,437 people. GlaxoSmithKline PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

GlaxoSmithKline PLC Leadership Team

Vindi Banga, Senior Independent Non-Executive Director
Lynn Elsenhans, Independent Non-Executive Director
Luke Miels, President - Global Pharmaceuticals
Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director
Daniel Podolsky, Non-Executive Independent Director
Emma Walmsley, Chief Executive Officer, Executive Director
Luc Debruyne, President - Global Vaccines
Andrew Witty, CEO, Executive Director
Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare
Charles Bancroft, Non-Executive Director
Roy Anderson, Non-Executive Independent Director
Philip Hampton, Independent Non-Executive Director
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox, Non-Executive Independent Director
Bill Louv, Senior Vice President - Core Business Services
Diana Conrad, Senior Vice President - Human Resources
Roger Connor, President - Global Manufacturing & Supply
Abbas Hussain, President Global Pharmaceuticals
Phil Thomson, Senior Vice President - Global Communications
Judy Lewent, Non-Executive Independent Director
Hans Wijers, Independent Non-Executive Director
Stephanie Burns, Non-Executive Independent Director
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Urs Rohner, Non-Executive Independent Director
Marvinder Banga, Senior Non-Executive Independent Director
Deryck Maughan, Senior Independent Non-Executive Director
Jesse Goodman, Non-Executive Independent Director
Laurie Glimcher, Non-Executive Independent Director
Nick Hirons, Senior Vice President - Global Ethics and Compliance
Sally Jackson, Senior Vice President - Global Communications and CEO Office
James Ford, Senior Vice President General Counsel
Victoria Whyte, Company Secretary
Daniel Troy, Sr. VP and General Counsel
Shah Hussain, President - Europe, Japan & EMAP
Manvinder Banga, Non-Executive Director
David Redfern, Chief Strategy Officer
Patrick Vallance, President - Pharmaceuticals R&D
Stacey Cartwright, Non-Executive Independent Director
Regis Simard, President - Pharmaceutical Supply Chain
Jonathan Symonds, Independent Non-Executive Chairman of the Board
Iain Mackay, Chief Financial Officer, Executive Director
Karenann Terrell, Chief Digital & Technology Officer
Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare
Claire Thomas, Senior Vice President - Human Resources

Stock Performance Indicators

Current Sentiment - GSK

GlaxoSmithKline PLC Investor Sentiment

Predominant part of Macroaxis users are currently bullish on GlaxoSmithKline PLC. What is your judgment towards investing in GlaxoSmithKline PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page